BrainStorm CEO to Discuss Phase 3b ALS Trial at Maxim Healthcare Virtual Summit
BrainStorm CEO to Discuss Phase 3b ALS Trial at Maxim Healthcare Virtual Summit
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its participation in the 2024 Maxim Healthcare Virtual Summit. Chaim Lebovits, President and CEO of BrainStorm, will join Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group, for a Fireside Chat at 9:30 a.m. ET on October 15. During the session, Mr. Lebovits will provide an update on the planned Phase 3b clinical trial for NurOwn, the company's investigational cell therapy for ALS. This event presents a valuable opportunity to engage with the investment community and share in-depth insights into the upcoming trial.
神经退行性疾病成人干细胞疗法的领先开发商BrainStorm Cell Therapeutics Inc.（纳斯达克股票代码：BCLI）今天宣布参加2024年Maxim Healthcare虚拟峰会。BrainStorm总裁兼首席执行官查伊姆·莱博维茨将于美国东部时间10月15日上午9点30分与Maxim集团高级董事总经理兼生物技术研究主管杰森·麦卡锡博士一起进行炉边谈话。会议期间，莱博维茨先生将介绍该公司针对肌萎缩性侧索硬化症的研究性细胞疗法NuroWn计划进行的30期临床试验的最新情况。该活动为与投资界互动并分享对即将到来的试验的深入见解提供了宝贵的机会。
The Maxim Healthcare Summit will take place from October 15 to 17 and will bring together biotechnology, diagnostic, medical device, and healthcare information technology companies. Senior analysts will lead presentations and discussions, while engaging industry panels will focus on critical healthcare trends shaping the future of the industry.
Maxim Healthcare峰会将于10月15日至17日举行，将汇集生物技术、诊断、医疗设备和医疗保健信息技术公司。高级分析师将主持演讲和讨论，而引人入胜的行业小组将重点关注塑造该行业未来的关键医疗保健趋势。
